Inhibitory effects of 17beta-estradiol on production of both molecular and cellular factors in neuroinflammatory reaction in model of Parkinson's disease

• Autorzy: Ciesielska A. , Joniec L. , Cudna A. , Kurkowska-Jastrzebska L. , Sznejder A. , Zaremba N. , Czlonkowska A. , Czlonkowski A.
• Języki publikacji: EN

Abstrakty

EN

The neuroprotective action of 17β-estradiol (E2) against 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown in both female and male mice, however the exact mechanisms of that phenomenon remain obscured. We studied the chronic effects of E2 (0.25 mg per pellet, 21-days release) administered 7 days prior (Experiment 1) to or 3 days after (Experiment 2) MPTP intoxication (40 mg/kg, i.p.) in C57BL aged male mice on neurodegenerative and infl ammatory processes in nigrostriatal pathway. We estimated striatal: tyrosine hydroxylase (TH), glial fi brillary acidic protein (GFAP) content (Western blotting); cytokines (TNFα, TGFβ1, IFNγ), trophic factor (GDNF) gene expression (RT-PCR); CD4+ and CD8+ cells infl ux (immunohistochemistry) at 1, 7, 21 (Exp. 1) and 7, 21 (Exp. 2) days post intoxication. E2 exerted a neuroprotective effect upon nigrostriatal system when administered prior but also when administered after intoxication (E2 attenuated the MPTP-induced loss of TH). E2 also decreased the GFAP content. MPTP caused a rapid increase of TGFβ1, TNFα and IFNγ. Pre-treatment with E2 decreased the early expression of TGFβ1 and IFNγ but failed to suppress the MPTP-induced increase of TNFα. E2 pre-treatment also induced an increase of the GDNF and CD4+ cells infl ux to the injured brain areas but decreased the CD8+ cells infi ltration. The neuroprotective effects of E2 indicated in MPTP model might mediate through a modulation of neuroinfl ammatory reaction in lesioned nigrostriatal system.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2009
• Tom: 69
• Numer: 3
• Opis fizyczny: p.344-345

Twórcy

autor

Ciesielska A.

• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
• Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Joniec L.

• Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Cudna A.

• Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Kurkowska-Jastrzebska L.

• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
• Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Sznejder A.

• Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Zaremba N.

• Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Czlonkowska A.

• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
• Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Czlonkowski A.

• Department of Clinical and Experimental Pharmacology, Medical University of Warsaw, Warsaw, Poland